Recent News

• 05.23.2025 - Achieve 5 Marketing Wins with In-Market Signals Using PulseIQ™
• 05.22.2025 - Harnessing Identity Intelligence in Modern Marketing
• 05.14.2025 - Channel Therapeutics Announces Positive Efficacy Results for the Treatment of Eye Pain Using its NaV1.7 Inhibitor in Multiple Preclinical In Vivo Models
• 05.01.2025 - Channel Therapeutics Provides Announcement on 2024 Annual Report to Comply with NYSE American Listing Rules
• 04.17.2025 - Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics
• 12.20.2024 - Channel Therapeutics Highlights Differences Between NaV1.7 and NaV1.8 in Light of Recent Clinical Data on Suzetrigine
• 12.18.2024 - Channel Therapeutics Announces Positive Efficacy Data For a Depot Formulation of a NaV1.7 Inhibitor in a Preclinical In Vivo Nerve Block Model

Recent Filings

• 05.13.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.09.2025 - PREM14C Preliminary information statements relating to merger or acquisition
• 05.01.2025 - EX-99.1 EX-99.1
• 05.01.2025 - 8-K Current report
• 04.17.2025 - 8-K Current report
• 04.17.2025 - EX-99.1 EX-99.1
• 04.15.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.15.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.27.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.03.2025 - 8-K Current report